241 related articles for article (PubMed ID: 240033)
21. IFN-gamma- and cell-to-cell contact-dependent cytotoxicity of allograft-induced macrophages against syngeneic tumor cells and cell lines: an application of allografting to cancer treatment.
Yoshida R; Yoneda Y; Kuriyama M; Kubota T
J Immunol; 1999 Jul; 163(1):148-54. PubMed ID: 10384111
[TBL] [Abstract][Full Text] [Related]
22. Stimulation of genetic resistance to marrow grafts in mice by interferon-alpha/beta.
Afifi MS; Kumar V; Bennett M
J Immunol; 1985 Jun; 134(6):3739-45. PubMed ID: 2985694
[TBL] [Abstract][Full Text] [Related]
23. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments.
Weiss L; Reich S; Slavin S
Cytokines Cell Mol Ther; 1999 Sep; 5(3):145-52. PubMed ID: 10641572
[TBL] [Abstract][Full Text] [Related]
24. Lack of suppressor cell activity in the spleens of mice with radiation-induced osteogenic sarcomas.
Argyris BF; Reif AE
Cancer Res; 1981 Mar; 41(3):839-44. PubMed ID: 6450637
[TBL] [Abstract][Full Text] [Related]
25. The immunological basis of tumor rejection: the absolute dependence of the effector arm on sensitized T cells after chemoimmunotherapy of a murine sarcoma.
Evans R; Duffy T
J Immunol; 1985 Jun; 134(6):4255-60. PubMed ID: 3872913
[TBL] [Abstract][Full Text] [Related]
26. A new strategy for treatment of malignant tumor: intra-bone marrow-bone marrow transplantation plus CD4- donor lymphocyte infusion.
Suzuki Y; Adachi Y; Minamino K; Zhang Y; Iwasaki M; Nakano K; Koike Y; Ikehara S
Stem Cells; 2005 Mar; 23(3):365-70. PubMed ID: 15749931
[TBL] [Abstract][Full Text] [Related]
27. Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors.
Gabrilovich DI; Nadaf S; Corak J; Berzofsky JA; Carbone DP
Cell Immunol; 1996 May; 170(1):111-9. PubMed ID: 8665591
[TBL] [Abstract][Full Text] [Related]
28. Immune inhibition of allogeneic lymphoma cells in the peritoneal cavity of mice.
Fioretti MC; Libarati M; Bonmassar E; Cudkowicz G
Cancer Res; 1975 Jan; 35(1):30-6. PubMed ID: 1089042
[TBL] [Abstract][Full Text] [Related]
29. Distribution of radiolabeled alloantibodies in mice bearing 3-methylcholanthrene-induced sarcoma.
Buchsbaum DJ; Walker PC; Johnson EA
Cancer Res; 1979 Sep; 39(9):3363-8. PubMed ID: 476667
[TBL] [Abstract][Full Text] [Related]
30. Leucyl-leucine methyl ester treatment of donor cells permits establishment of immunocompetent parent----F1 chimeras that are selectively tolerant of host alloantigens.
Thiele DL; Calomeni JA; Lipsky PE
J Immunol; 1987 Oct; 139(7):2137-42. PubMed ID: 3309052
[TBL] [Abstract][Full Text] [Related]
31. Allogeneic cell therapy for a murine mammary carcinoma.
Morecki S; Yacovlev E; Diab A; Slavin S
Cancer Res; 1998 Sep; 58(17):3891-5. PubMed ID: 9731499
[TBL] [Abstract][Full Text] [Related]
32. Regeneration of transplanted allogeneic hemopoietic progenitor cells in mouse spleen organ cultures.
von Melchner H; Bartlett PF
Exp Hematol; 1981 Nov; 9(10):978-89. PubMed ID: 6118283
[TBL] [Abstract][Full Text] [Related]
33. Cell-mediated cytotoxic responses of spleen cells from mice bearing primary, chemically induced tumors.
Civin CI; Dorfman N; Eggers A; Fink K; Penvose D; Hsu CK; Wunderlich JR
J Immunol; 1979 Dec; 123(6):2550-7. PubMed ID: 159318
[TBL] [Abstract][Full Text] [Related]
34. Specific inhibition of hybrid resistance in F1 hybrid mice pretreated with parent strain spleen cells. I. Induction of a nylon-adherent, Thy-1+Lyt-1+2- suppressor cell.
Kosmatopoulos K; Orbach-Arbouys S
J Immunol; 1987 Feb; 138(3):704-12. PubMed ID: 2879865
[TBL] [Abstract][Full Text] [Related]
35. Tumor acceptance modified by passage in hybrids with graft-versus-host reaction.
Jacobs BB; Parks RC
Exp Hematol; 1978 Nov; 6(10):785-90. PubMed ID: 33818
[TBL] [Abstract][Full Text] [Related]
36. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
Sensi M; Orosz CG; Bach FH
J Immunol; 1984 Jun; 132(6):3218-25. PubMed ID: 6202778
[TBL] [Abstract][Full Text] [Related]
37. The role of T cells in allografted tumor rejection: IFN-gamma released from T cells is essential for induction of effector macrophages in the rejection site.
Yoneda Y; Yoshida R
J Immunol; 1998 Jun; 160(12):6012-7. PubMed ID: 9637516
[TBL] [Abstract][Full Text] [Related]
38. Alien histocompatibility determinants on the cell surface of sarcomas induced by methylcholanthrene. I. In vivo studies.
Parmiani G; Invernizzi G
Int J Cancer; 1975 Nov; 16(5):756-67. PubMed ID: 52628
[TBL] [Abstract][Full Text] [Related]
39. Induction of bone marrow allograft rejection and hybrid resistance in nonresponder recipients by antibody: is there evidence for a dual receptor interaction in acute marrow graft rejection?
Dennert G; Anderson CG; Warner J
J Immunol; 1986 Jun; 136(11):3981-6. PubMed ID: 3517162
[TBL] [Abstract][Full Text] [Related]
40. T killer cells play a role in allogeneic bone marrow graft rejection but not in hybrid resistance.
Dennert G; Anderson CG; Warner J
J Immunol; 1985 Dec; 135(6):3729-34. PubMed ID: 3905963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
